{"analyses":[{"ciLowerLimit":"-7.105","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-0.424","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.705","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.03","paramType":"Slope","paramValue":"-3.764","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.222","value":"93.2892"},{"groupId":"OG001","spread":"2.9775","value":"90.6135"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0577","value":"90.3088"},{"groupId":"OG001","spread":"2.9025","value":"96.8356"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0069","value":"88.984"},{"groupId":"OG001","spread":"3.0406","value":"96.0616"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.4333","value":"93.9267"},{"groupId":"OG001","spread":"3.1257","value":"91.6458"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.4341","value":"89.2513"},{"groupId":"OG001","spread":"3.6562","value":"94.0647"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"Echocardiographic measure of left ventricular (LV) afterload based on LV pressure (P), volume (V), and wall thickness (T), calculated by the formula (P x V)/T, which equals the number referred to below in the Measure Type. The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Left Ventricular End-systolic Wall Stress","type":"SECONDARY","unitOfMeasure":"g/cm^2"}